2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170365
    HPK1-IN-55 3048537-58-9 98%
    HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects.
    HPK1-IN-55
  • HY-170370
    RORγt inverse agonist 34 2247604-77-7 98%
    RORγt inverse agonist 34 (compound 5a) is a RORγt inverse agonist with an IC50 of 0.094 μM for RORγt-LBD. RORγt inverse agonist 34 is used for psoriasis research.
    RORγt inverse agonist 34
  • HY-17037S
    Pirenzepine-d8 1189944-02-2 98%
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-170396
    ABCG2-IN-4 2559759-63-4 98%
    ABCG2-IN-4 (Compound K31) is an orally active inhibitor for ABCG2, which reduces the release of Protoporphyrin IX (PPIX) (HY-B1247) from erythrocytes into plasma, and prevents the reduces phototoxicity. ABCG2-IN-4 exhibits anti-inflammatory and antioxidant activity in mouse models.
    ABCG2-IN-4
  • HY-170397
    ADORA2A/PDE4D-IN-1 1321513-73-8 98%
    ADORA2A/PDE4D-IN-1 (Compound 9) is a dual inhibitor for adenosine A2a receptor (ADORA2A) and phosphodiesterase 4D (PDE4D). ADORA2A/PDE4D-IN-1 can be used in research of bronchial asthma.
    ADORA2A/PDE4D-IN-1
  • HY-170409
    BNN27 1195795-81-3 98%
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.
    BNN27
  • HY-170426
    DGKζ-IN-9 3062706-10-6 98%
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-9
  • HY-170427
    DGKζ-IN-10 3062708-86-2 98%
    DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-10
  • HY-17042B
    (S)-Cetirizine dihydrochloride 163837-48-7 98%
    (S)-Cetirizine dihydrochloride ((S)-P071) is an orally active antagonist of the histamine H1 receptor with a Ki value of 39.1 nM. (S)-Cetirizine dihydrochloride exerts anti-allergic activity by binding to the histamine H1 receptor and blocking the action of histamine. (S)-Cetirizine dihydrochloride is promising for research of allergic diseases such as allergic rhinitis.
    (S)-Cetirizine dihydrochloride
  • HY-170440
    ATV2301 3049172-60-0 98%
    ATV2301 is an orally active anti-influenza agent (EC50, H1N1 = 1.88 nM, H3N2 = 4.77 nM). ATV2301’s anti-influenza activity is due to its effects on polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp).
    ATV2301
  • HY-170447
    NOD1 antagonist-2 98%
    NOD1 antagonist-2 (compound 66) is an orally active selective antagonist of both human and mouse NOD1. NOD1 antagonist-2 (compound 66) antagonizes NOD1-induced NF-κB and MAPK pathways.
    NOD1 antagonist-2
  • HY-170489
    Antifungal agent 123 98%
    Antifungal agent 123 (Compound 4b) exhibits good affinity to the oxidoreductase of Staphylococcus aureus or the membrane protein of Candida albicans, exhibits antibacterial and antifungal activities. Antifungal agent 123 scavenges free radical, exhibits antioxidant efficacy. Antifungal agent 123 inhibits the TLR signaling pathway, and exhibits anti-inflammatory efficacy.
    Antifungal agent 123
  • HY-170492
    sEH inhibitor-19 98%
    sEH inhibitor-19 (Compound (R)-14i) is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 1.2 nM. sEH inhibitor-19 inhibits the expression of TNF-α and IL-6, exhibits anti-inflammatory activity in mouse acute pancreatitis or Carrageenan (HY-125474)-induced edema models.
    sEH inhibitor-19
  • HY-170516
    GLP-1 receptor agonist 16 2902596-52-3 98%
    GLP-1 receptor agonist 16 (Example 53) is a GLP-1 agonist. GLP-1 receptor agonist 16 can be used for the research of diabetes, obesity, or nonalcoholic steatohepatitis-related diseases[1].
    GLP-1 receptor agonist 16
  • HY-170525
    CD73-IN-19 333329-22-9 98%
    CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (Ki is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases.
    CD73-IN-19
  • HY-170529
    NLRP3-IN-61 3060585-94-3 98%
    NLRP3-IN-61 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-61 inhibits pyroptosis in THP-1 cell with an IC50 of 12.6 nM, inhibits IL-β release with an IC50 of 25.3 nM.
    NLRP3-IN-61
  • HY-170530
    NLRP3-IN-62 3059965-71-5 98%
    NLRP3-IN-62 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-62 inhibits pyroptosis in THP-1 cell with an IC50 of 0.7 nM, inhibits IL-β release with an IC50 of 108.5 nM.
    NLRP3-IN-62
  • HY-170532
    NLRP3-IN-63 3064696-02-9 98%
    NLRP3-IN-63 (Compound 7) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 13 nM.
    NLRP3-IN-63
  • HY-170533
    NLRP3-IN-64 3047549-19-6 98%
    NLRP3-IN-64 (Compound 2) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 5 nM.
    NLRP3-IN-64
  • HY-170535
    NLRP3-IN-65 3052859-81-8 98%
    NLRP3-IN-65 (compound 41) is a potent NLRP3 inhibitor.
    NLRP3-IN-65
Cat. No. Product Name / Synonyms Application Reactivity